1) Can changes in functional brain networks in patients with and without hallucinations from several psychiatric, neurological, and perceptual disorders be detected? And if so, what is the pattern of change in these diseases?2) Are specific changes…
ID
Source
Brief title
Condition
- Hearing disorders
- Movement disorders (incl parkinsonism)
- Schizophrenia and other psychotic disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
1) Detecting and characterizing functional network changes in different
diagnoses underlying hallucinations. Questions that are addressed are: can
changes in local and global connectivity be detected in brain networks of
patients with and without hallucinations for the different diagnoses? Can brain
regions be identified which are more affected than others and can regional
differences in network change be related to region-specific properties of the
network?
2) Relating specific network changes to specific subtypes of hallucinations. If
patterns of change in connectivity or regional changes in brain networks are
found within or between different diagnoses, can a relationship with certain
subtypes of hallucinations be established?
Secondary outcome
NA
Background summary
Hallucinations occur in many patients with different kinds of diseases,
including psychiatric, neurological and perceptual impairment, as well as in
healthy individuals. The origin of these hallucinations is only partly
understood. This prevents correct prediction of treatment response and hampers
the development of new, more effective treatment strategies. At present,
treatment is mainly defined by the underlying diagnosis, but different subtypes
of hallucinations resulting from different neuropathology may exist across
diagnostic entities, and be responsive to different treatment strategies.
Understanding the origin of these subtypes with the use of MEG
(magnetoencephalography, a recording of magnetic fields related to brain
activity) and modern network theory can help to make rational treatment
decisions on an individual basis and enhance the development of innovative
treatment paradigms.
Study objective
1) Can changes in functional brain networks in patients with and without
hallucinations from several psychiatric, neurological, and perceptual disorders
be detected? And if so, what is the pattern of change in these diseases?
2) Are specific changes in functional networks related to different subtypes of
hallucinations? We propose to compare functional networks of patients with and
without hallucinations, and of hallucinating subjects of different disorders.
Study design
This study is an observational cross-sectional study using MEG and modern
network theory to study the neural correlates of hallucinations across
different disorders, and to compare these MEG findings to matched subjects
without hallucinations.
Study burden and risks
MEG measurements are non-invasive, taking approximately 30 minutes. The
procedure is not painful in any way, is not considered to be difficult or
stressful, and has negligible risks. The participants are asked to visit VU
Medical Center for the investigations, meaning one extra trip to the hospital.
If possible, the visit will be combined with clinical appointments. There is no
individual benefit from the MEG. The MEG recordings have a higher spatial
resolution compared to the conventional electroencephalography (EEG). Total
visit time, including preparations, and a break between measurements, will be
approximately 2,5 hours. The potential benefit to society in the future is
considerable if the findings lead to optimization of treatment strategies and
accurate prediction of treatment response.
Heidelberglaan 100
Utrecht 3508 GA
NL
Heidelberglaan 100
Utrecht 3508 GA
NL
Listed location countries
Age
Inclusion criteria
- Written informed consent for the study NL42959
- For the patient group: diagnosis of one of the following disorders: schizophrenia spectrum disorder, Parkinson*s disease, dementia with Lewy bodies, hearing loss
- For the patient control group: no hallucinations in the past two years, and lifetime no more than one week and one episode of hallucinations
- For healthy controls: no hallucinations in the past two years, and lifetime no more than one week and one episode of hallucinations, and no current psychiatric, neurological or perceptual disorder
- Mentally competent, as determined by researcher during informed consent meeting preceding study visit
- Written informed consent
- Age * 18;In case of the diagnostic group with hallucinations: patients have to have experienced one of these symptoms at least once within the last 30 days.
Exclusion criteria
- Age < 18
- Participants that cannot read, speak or understand Dutch
- Mentally incompetent individuals who are not capable to provide informed consent, as determined by researcher during informed consent meeting preceding study visit
- For the patient control group: history of hallucinations in past two years and/or lifetime more than one week and one episode of hallucinations
- For the healthy controls: history of hallucinations in past two years and/or lifetime more than one week and one episode of hallucinations, and/or any current psychiatric, neurological or perceptual disorder
- Conditions that will cause excessive MEG artifacts (cardiac pacemaker / cardiac or neural defibrillators, metal fragments in the eyes, metal plates, pins or bolts in head, any magnetic implantation / implantations made from iron (ferrous products)
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL56810.029.16 |